Medical insurance payment standard will be implemented and pharmaceutical enterprises will face pressure of price reduction

[China Pharmaceutical network industry trends] "medical insurance payment standards will be published together with the medical insurance catalog." Yu Mingde, President of China Pharmaceutical Enterprise Management Association, told reporters, "the Ministry of human resources and social security and other ministries and commissions formulate rules, provincial governments formulate specific policies, and coordinate regional payment methods." (the payment standard of medical insurance will be implemented, and pharmaceutical enterprises will face the pressure of price reduction Photo source: Baidu photo) Recently, the Ministry of human resources and social security, together with the health and Family Planning Commission, once again solicited opinions from the provincial departments on the guiding opinions on the formulation rules of drug payment standards for basic medical insurance (Draft for comments) (hereinafter referred to as draft for comments) It is expected that the formal draft of medical insurance payment standards will be released later than March, and the new version of medical insurance drug catalog is expected to be released at the same time Different from the previous proportional reimbursement method, the highlight is that the price difference between the medical insurance payment standard and the drug sales price of the hospital allows the hospital to retain Therefore, hospitals have the power to suppress drug prices "Medical insurance payment standard" refers to the benchmark for medical insurance fund to pay for drugs when the insured personnel of the three basic medical insurance use the drugs in the medical insurance catalog According to the payment standard of drugs and the payment regulations of medical insurance, the medical insurance fund pays drug expenses to designated medical institutions of basic medical insurance and designated retail pharmacies (collectively referred to as "designated institutions") When Medicare drugs are paid in proportion, the higher the drug price is, the more profitable the hospital will be; when there is no drug addition, the higher the drug price is, the more grey profit space the drug supplier will give the hospital The implementation of medical insurance payment standard makes medical institutions become the main body to actively reduce the purchase price of drugs Because the medical institutions can master the real market demand of drugs, the efficiency of taking the medical institutions as the main body to reduce the price of drugs is higher than the bidding office and other non directly related government departments This is also the reason why the medical insurance payment standard can guide the formation of the real market price of drugs In this way, pharmaceutical companies will face greater pressure to reduce prices Industry insiders told reporters that for innovative drugs with better efficacy or difficult to replace, there is little pressure to reduce prices; high priced drugs with more substitutes face greater pressure to reduce prices For example, the imported original research drugs that have completed the consistency evaluation of generic drugs, the Chinese patent medicines that have more manufacturers, and some traditional Chinese medicine varieties that have more competitive substitutes all face greater pressure of price reduction.